Oklahoma Senate Bill SB1508

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

End-of-life care; creating the Compassionate Access to Medical Marijuana Act; requiring health care facilities to permit medical marijuana use by certain patients. Effective date.

Impact

If enacted, SB1508 will specifically empower health care facilities to accommodate the medical needs of terminally ill patients who possess valid medical marijuana licenses issued by the Oklahoma Medical Marijuana Authority. The bill prohibits smoking or vaping within the facilities while requiring compliance with existing state drug and medication regulations. Facilities must ensure that the use of medical marijuana is documented in patients' medical records and that appropriate safety measures, such as proper storage protocols, are in place. This mirrors broader trends toward integrating alternative medicines into mainstream health care.

Summary

Senate Bill 1508, known as the Compassionate Access to Medical Marijuana Act, seeks to amend Oklahoma law regarding the use of medical marijuana in health care facilities for terminally ill patients. The bill mandates that licensed health care facilities must allow patients diagnosed with terminal illnesses to utilize medical marijuana as part of their treatment protocol, provided they adhere to certain regulations outlined in the act. This legislation is a response to the growing need for access to alternative treatment options for patients facing end-of-life scenarios, aiming to enhance patient-centered care.

Contention

Key points of contention surrounding SB1508 relate to the restrictions it places on how medical marijuana can be consumed in care settings and the obligations it places on health care facilities. Critics of the bill may argue that the requirement to prohibit smoking or vaping could limit patient choice and comfort during their end-of-life care. Moreover, there may be concerns regarding the potential inconsistency with federal regulations concerning marijuana, as it remains a Schedule I substance under federal law, raising questions about the liability and enforcement challenges for health care providers who comply with state law while navigating federal restrictions.